文献速递前列腺癌

局限性前列腺癌手术与放疗后的生存和并发症:一项国际协作综述

Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review.
PubMed 文献 · Eur Urol · 2017-06-11

该国际协作批判性叙述综述评估了局限性前列腺癌(PCa)手术与放疗(RT)的比较有效性和危害。随机试验把握度不足以检测临床有意义的终点,且未显示总生存或PCa特异性生存差异;观察性研究一致显示根治性前列腺切除术的绝对生存获益,但受选择偏倚和残余混杂限制。两种治疗并发症均较常见。

要点

  • 随机试验未显示手术与放疗在总生存或PCa特异性生存上有差异。
  • 观察性研究显示根治性前列腺切除术有绝对生存获益,但存在选择偏倚。
  • 放疗后住院、泌尿/直肠肛门/其他大手术及继发癌更常见。

核心结论

  • 由于随机对照研究把握度不足及观察性研究固有的选择偏倚,目前或近期内无法明确回答哪种治疗能更好地控制PCa。
  • 无论采用何种治疗方式,PCa治疗后的并发症均相对常见,包括尿失禁和勃起功能障碍,以及住院、处理并发症的侵入性操作和继发恶性肿瘤。
  • 需要基于人群的结局研究而非临床试验数据来全面理解每种治疗方案的相对获益与风险。

研究设计与样本

  • 国际协作的批判性叙述综述(critical narrative review),检索并汇总相关文献证据。

主要发现

  • 随机试验把握度不足以检测临床有意义的终点,且未显示总生存或PCa特异性生存差异。
  • 观察性研究一致显示根治性前列腺切除术有绝对生存获益,但受选择偏倚和残余混杂限制。
  • 三项随机试验显示手术与放疗后健康相关生活质量相当。
  • 随机数据显示泌尿、勃起和肠道功能在长期(>5年)差异较少,但短期控尿和勃起功能手术后更差,短期泌尿困扰和肠道功能放疗后更差。
  • 放疗后住院、需泌尿/直肠肛门/其他大手术及继发癌更常见;常与放疗联用的雄激素剥夺治疗可能额外增加治疗相关发病率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 随机试验把握度不足以检测临床有意义的终点。
  • 观察性研究受选择偏倚和残余混杂误差限制。
  • 手术和放疗的技术创新在肿瘤学和功能获益方面显示不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evaluation of treatment options for localized prostate cancer (PCa) remains among the highest priorities for comparative effectiveness research. Surgery and radiotherapy (RT) are the two interventions most commonly used. OBJECTIVE: To provide a critical narrative review of evidence of the comparative effectiveness and harms of surgery and RT in the treatment of localized PCa. EVIDENCE ACQUISITION: A collaborative critical narrative review of the literature was conducted. EVIDENCE SYNTHESIS: Evidence to clearly guide treatment choice in PCa remains insufficient. Randomized trials are underpowered for clinically meaningful endpoints and have demonstrated no difference in overall or PCa-specific survival. Observational studies have consistently demonstrated an absolute survival benefit for men treated with radical prostatectomy, but are limited by selection bias and residual confounding errors. Surgery and RT are associated with comparable health-related quality of life following treatment in three randomized trials. Randomized data regarding urinary, erectile, and bowel function show few long-term (>5 yr) differences, although short-term continence and erectile function were worse following surgery and short-term urinary bother and bowel function were worse following RT. There has been recent recognition of other complications that may significantly affect the life trajectory of those undergoing PCa treatment. Of these, hospitalization, the need for urologic, rectoanal, and other major surgical procedures, and secondary cancers are more common among men treated with RT. Androgen deprivation therapy, frequently co-administered with RT, may additionally contribute to treatment-related morbidity. Technological innovations in surgery and RT have shown inconsistent oncologic and functional benefits. CONCLUSIONS: Owing to underpowered randomized control studies and the selection biases inherent in observational studies, the question of which treatment provides better PCa control cannot be definitively answered now or in the near future. Complications following PCa treatment are relatively common regardless of treatment approach. These include the commonly identified issues of urinary incontinence and erectile dysfunction, and others including hospitalization and invasive procedures to manage complications and secondary malignancies. Population-based outcome studies, rather than clinical trial data, will be necessary for a comprehensive understanding of the relative benefits and risks of each therapeutic approach. PATIENT SUMMARY: Surgery and radiotherapy are the most common interventions for men diagnosed with prostate cancer. Comparisons of survival after these treatments are limited by various flaws in the relevant studies. Complications are common regardless of the treatment approach.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Wallis CJD, Glaser A, Hu JC, et al. Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. Eur Urol. 2017. PMID: 28610779. doi:10.1016/j.eururo.2017.05.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。